Vasopressin Receptor
Signaling Pathway Map
Research Area
- Inhibitory Selectivity
- Solubility
| Catalog No. | Product Name | Solubility(25°C) | ||
|---|---|---|---|---|
| Water | DMSO | Alcohol | ||
| S2116 | Conivaptan HCl | <1 mg/mL | 107 mg/mL | 7 mg/mL |
| S2593 | Tolvaptan | <1 mg/mL | 89 mg/mL | 6 mg/mL |
| S2920 | Mozavaptan | <1 mg/mL | 1 mg/mL | 1 mg/mL |
Isoform-specific Inhibitors
Vasopressin Receptor Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2116 |
Conivaptan HClConivaptan HCl is an orally active, non-peptide, vasopressin V1A and V2 receptor antagonist, used in the treatment of euvolemic and hypervolemic hyponatremia. |
Select hit drugs from each class identified from the Selleck screen were assayed at 0.25X, 0.5X, and 1X MIC for their ability to prevent biofilm formation in vitro. Data were normalized to DMSO control. * p<0.05 (Student’s t-Test; two-tailed).
|
|
| S2593 |
TolvaptanTolvaptan is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia. |
Immunoblots of inner medullas from control and tolvaptan-treated rats. Each lane was loaded with a sample from a different rat. Tolvaptan (2.5 mg/day) or vehicle was infused for 4 days. Loading: aquaporin-2 (AQP2), 15 μg; AQP3, 20 μg; AQP4, 25 μg; and urea transporter UT-A1, 25 μg. Values are normalized band densities covering all bands (means ± SE). *Statistical significance (P < 0.05, t-test).
|
|
| S2920 |
MozavaptanMozavaptan is a novel competitive vasopressin receptor antagonist for both V1 and V2 receptors with IC50 of 1.2 μM and 14 nM, respectively. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2116 |
Conivaptan HClConivaptan HCl is an orally active, non-peptide, vasopressin V1A and V2 receptor antagonist, used in the treatment of euvolemic and hypervolemic hyponatremia. |
2017, AAC.01674-17 |
Select hit drugs from each class identified from the Selleck screen were assayed at 0.25X, 0.5X, and 1X MIC for their ability to prevent biofilm formation in vitro. Data were normalized to DMSO control. * p<0.05 (Student’s t-Test; two-tailed).
|
| S2593 |
TolvaptanTolvaptan is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia. |
2015, 309(5):F474-83 2014, 306(3):F359-66 |
Immunoblots of inner medullas from control and tolvaptan-treated rats. Each lane was loaded with a sample from a different rat. Tolvaptan (2.5 mg/day) or vehicle was infused for 4 days. Loading: aquaporin-2 (AQP2), 15 μg; AQP3, 20 μg; AQP4, 25 μg; and urea transporter UT-A1, 25 μg. Values are normalized band densities covering all bands (means ± SE). *Statistical significance (P < 0.05, t-test).
|
| S2920 |
MozavaptanMozavaptan is a novel competitive vasopressin receptor antagonist for both V1 and V2 receptors with IC50 of 1.2 μM and 14 nM, respectively. |
